HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

LyP-1-conjugated doxorubicin-loaded liposomes suppress lymphatic metastasis by inhibiting lymph node metastases and destroying tumor lymphatics.

Abstract
Lymphatic metastasis can be greatly promoted by metastases growth and lymphangiogenesis in lymph nodes (LNs). LyP-1, a cyclic peptide, is able to specifically bind with tumor cells and tumor lymphatics in metastatic LNs. This work aimed to use LyP-1-conjugated liposomes (L-LS) loaded with doxorubicin (DOX) (L-LS/DOX) to suppress lymphatic metastasis by inhibiting both metastases and tumor lymphatics in LNs. L-LS were prepared and exhibited sizes around 90 nm and spherical morphology as characterized by transmission electron microscopy. The in vitro cellular studies showed that LyP-1 modification obviously increased liposome uptake by MDA-MB-435 tumor cells and enhanced the cytotoxicity of liposomal DOX. A popliteal and iliac LN metastases model was successfully established by subcutaneous inoculation of tumor cells to nude mice. The immunofluorescence staining analysis indicated that LyP-1 modification enabled specific binding of liposome with tumor lymphatics and enhanced the destroying effect of liposomal DOX on tumor lymphatics. The in vivo fluorescence imaging and pharmacodynamic studies showed that LyP-1 modification increased liposome uptake by metastatic LNs and that L-LS/DOX significantly decreased metastatic LN growth and LN metastasis rate. These results suggested that L-LS/DOX were an effective delivery system for suppressing lymphatic metastasis by simultaneously inhibiting LN metastases and tumor lymphatics.
AuthorsZhiqiang Yan, Changyou Zhan, Ziyi Wen, Linglin Feng, Fei Wang, Yu Liu, Xiangkun Yang, Qing Dong, Min Liu, Weiyue Lu
JournalNanotechnology (Nanotechnology) Vol. 22 Issue 41 Pg. 415103 (Oct 14 2011) ISSN: 1361-6528 [Electronic] England
PMID21914940 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antibiotics, Antineoplastic
  • Liposomes
  • LyP-1 peptide
  • Peptides, Cyclic
  • Doxorubicin
Topics
  • Animals
  • Antibiotics, Antineoplastic (administration & dosage, pharmacology, therapeutic use)
  • Cell Line, Tumor
  • Cell Survival (drug effects)
  • Doxorubicin (administration & dosage, pharmacology, therapeutic use)
  • Humans
  • Liposomes (chemistry, ultrastructure)
  • Lymph Nodes (drug effects, pathology)
  • Lymphatic Metastasis (pathology, prevention & control)
  • Male
  • Mice
  • Mice, Inbred BALB C
  • Neoplasms (drug therapy, pathology)
  • Peptides, Cyclic (chemistry, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: